<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70572">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02007941</url>
  </required_header>
  <id_info>
    <org_study_id>19RI113017</org_study_id>
    <nct_id>NCT02007941</nct_id>
  </id_info>
  <brief_title>Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects</brief_title>
  <official_title>An Open-label, Non-randomized, Parallel-group Design Clinical Trial for Comparative Evaluation of Pharmacokinetics After CKD-501 Between Patients With Renal Impairment and Control Subjects With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess between the renal impaired patients and normal renal
      function subjects comparetive evaluation to Pharmacokinetics after CKD-501 Future, When
      prescription CKD-501 to renal impaired patient,  It will be guidelines to provide a basis of
      instructions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, Non-randomized, Open, Parallel-Group Clinical trial
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The pharmacokinetic( Cmax, AUCt ) of lobeglitazone(CKD-501)  Between Renal Impaired patients and Normal Renal function subjects</measure>
    <time_frame>0-48 hrs</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood sampling timepoint : (Day 1) 0hr, 0.33hr, 0.66hr, 1hr, 1.5hr, 2hr, 3hr, 6hr, 12hr, 24hr (Day 2)36hr (Day3)48hr- total 12 timepoints per period
Additional Blood sampling for unbound fraction analysis : (Day 1) 1hr, 6hr, 12hr
Urine collection  : (Day 1)0-6hr, 6-12hr, 12-24hr (Day 2) 24-36hr, 36-48hr</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetic( Cmax, AUCt ) of main metabolites(M7) of CKD-501  Between Renal Impaired patients and Normal Renal function subjects</measure>
    <time_frame>0-48 hrs</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood sampling timepoint : (Day 1) 0hr, 0.33hr, 0.66hr, 1hr, 1.5hr, 2hr, 3hr, 6hr, 12hr, 24hr (Day 2)12hr (Day3)0hr- total 12 timepoints per period
Urine collection  : (Day 1)0-6hr, 6-12hr, 12-24hr (Day 2) 24-36hr, 36-48hr</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Renal Impairment</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>End Stage Renal Disease(ESRD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-501 will be administered to patients who have required dialysis and non-dialysis eGFR(estimate glomerular filtration rate ) is Less than 15.
First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal renal function</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CKD-501 will be administered to normal renal function subject  who have eGFR(estimate glomerular filtration rate ) of 90 or more.
First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-501 will be administered to patients who have eGFR(estimate glomerular filtration rate ) is 60 to 89 that.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-501 will be administered to patients who have  eGFR(estimate glomerular filtration rate ) is 30 to 59 that.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-501 will be administered to patients who have  eGFR(estimate glomerular filtration rate ) is 15 to 29 that.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-501</intervention_name>
    <description>From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .</description>
    <arm_group_label>End Stage Renal Disease(ESRD)</arm_group_label>
    <arm_group_label>normal renal function</arm_group_label>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_label>Morderate renal impairment</arm_group_label>
    <arm_group_label>severe renal impairment</arm_group_label>
    <other_name>Lobeglitazone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        All subjects:

          -  Adult males or females, 20 - 65 years of age (inclusive);

          -  Body mass index (BMI) range of approximately 18.5-29.9 kg/㎡ (inclusive);

          -  Agreement with written informed consent

          -  Agree to Medically acceptable method of contraception during clinical trials

        Normal Renal Function subjects:

          -  Matched to renal impaired patients(ESRD) in the study by age (±7 years), sex and BMI

          -  Medically healthy with clinically insignificant screening results (e.g., laboratory
             profiles, medical history, EKG, physical examination);

          -  eGFR ≥ 90 mL/min/1.73mE2;

        Renally impaired subjects:

          -  Matched to renal impaired patients(ESRD) in the study by age (±7 years), sex and BMI

          -  Subjects with mild renal impairment (eGFR 60-89 mL/min/1.73mE2) OR moderate renal
             impairment (eGFR 30-59 mL/min/1.73mE2) OR severe renal impairment (eGFR 15-29
             mL/min/1.73mE2)  OR dialysis end stage renal disease(ESRD)

        Exclusion Criteria

        All subjects:

          -  The subject's systolic blood pressure is outside the range of 100-180mmHg, or
             diastolic blood pressure is outside the range of 50-110mmHg

          -  Repeatedly Screening ECG parameters (PR ≥ 210 mse,QRS ≥ 120 msec, QTcF ≥ 500 msec)

          -  Repeatedly lab(AST &gt;1.25xULN, ALT&gt;1.25xULN ,Total bilirubin &gt;1.5xULN)

          -  A positive pre-study drug screen.(amphetamines, barbiturates, cocaine, opiates,
             cannabinoids, benzodiazepin)

          -  Clinically significant allergic diseases or History of thiazolidinedione class's
             anaphylaxis reactions

          -  Can not stop to be taking caffeine (caffeine &gt; 400mg/day), drinking(alcohol &gt; 30
             g/day)  or severe heavy smoker(cigarette &gt; 10 cigarettes/day) during clinical trials

          -  Consumption of food which may affect study within 7 days prior to first dose of study
             medication or taking a dietary supplement now or continued.

          -  Consumption of drug which may affect study within 7 days prior to first dose of study
             medication.

          -  Previously donate whole blood within 60 days or component blood within 30 days prior
             to first dose of study medication.

          -  blood transfusion within 30 days prior to first dose of study medication.

          -  Subjects with participation in another clinical trial within 60 days prior to the
             study

          -  An impossible one who participates in clinical trial by Principal investigator's
             decision

        Normal Renal Function subjects:

          -  Subjects with a history of chronic disease or an acute illness within 28 days of
             study medication administration

          -  Subjects with a history of gastrointestinal disease effected study medication or
             surgery(except appendectomy, hernia surgery)

          -  Current or chronic history of liver disease or ascites or hepatic encephalopathy

        Renally impaired subjects:

          -  Type I diabetes, Diabetic ketoacidosis, diabetic coma or a history of coma
             (controllable Type II diabetes including possible)

          -  Uncontrollable hypertension or severe heart failure

          -  require treatment with steroid or immunosuppressive drug

          -  History of renal transplant or undergoing other dialysis method  except hemodialysis

          -  Needs treatment for acute disease, uncontrolled other disease or diabetic
             complications

          -  Current or chronic history of liver disease or ascites or hepatic encephalopathy

          -  Subjects with a history of chronic disease or an acute illness within 28 days of
             study medication administration

          -  Subjects with a history of gastrointestinal disease effected study medication or
             surgery(except appendectomy, hernia surgery)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Kuk Shin, Ph.D. M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Inje University Busan Paik Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jae Kuk Shin, Ph. D. M.D</last_name>
      <phone>82-51-890-6709</phone>
      <email>phshinjg@inje.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jae Kuk Shin, Ph.D. M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 6, 2013</lastchanged_date>
  <firstreceived_date>December 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
